Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ovid Therapeutics Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $75.00K Beat $50.00K Estimate

Author: Benzinga Newsdesk | August 04, 2023 08:05am
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 14.29 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $75.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 50.00 percent.

Posted In: OVID


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist